Crossmark Global Holdings Inc. Sells 4,587 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Crossmark Global Holdings Inc. lowered its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 44.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,848 shares of the biotechnology company's stock after selling 4,587 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Ascendis Pharma A/S were worth $911,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ASND. Envestnet Asset Management Inc. raised its holdings in Ascendis Pharma A/S by 12.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 11,851 shares of the biotechnology company's stock valued at $1,847,000 after acquiring an additional 1,274 shares in the last quarter. Penserra Capital Management LLC bought a new stake in Ascendis Pharma A/S in the 1st quarter valued at $420,000. GF Fund Management CO. LTD. increased its holdings in Ascendis Pharma A/S by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,544 shares of the biotechnology company's stock valued at $241,000 after buying an additional 278 shares during the period. New Wave Wealth Advisors LLC bought a new stake in Ascendis Pharma A/S in the 1st quarter valued at $222,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in Ascendis Pharma A/S by 24.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 189,613 shares of the biotechnology company's stock valued at $28,713,000 after buying an additional 36,875 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ASND. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Oppenheimer reissued an "outperform" rating and set a $224.00 price objective (up previously from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. Citigroup boosted their target price on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $223.07.

Ascendis Pharma A/S Stock Performance

ASND stock traded up $1.33 during midday trading on Monday, hitting $176.29. 144,432 shares of the company's stock were exchanged, compared to its average volume of 487,723. The stock's fifty day moving average price is $168.27 and its 200-day moving average price is $153.60. The company has a market cap of $10.78 billion, a PE ratio of -28.07 and a beta of 0.38. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.